Quinone Derivatives Mitigate Hepatic Metabolism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for mitochondrial dysfunction primarily alleviate symptoms rather than addressing the underlying dysfunction, and existing compounds like idebenone have poor bioavailability and high liver metabolism, necessitating the development of more effective and specific treatments for mitochondrial-related diseases.
Innovation Solution
Development of compounds of Formula (I) and their pharmaceutical compositions that modulate, enhance, and restore mitochondrial function, offering prophylaxis and treatment for diseases associated with mitochondrial dysfunction, including primary, neurodegenerative, metabolic, and psychiatric disorders, through specific chemical structures and preparation processes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If idebenone is used to treat mitochondrial dysfunction, then some therapeutic effect is achieved, but bioavailability is poor and liver metabolism is excessive
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of quinone compounds (changing molecular weight, lipophilicity, and metabolic stability parameters) to develop compounds with improved bioavailability and reduced first-pass metabolism while maintaining mitochondrial therapeutic effects
Solution Approach 2:
The patent creates composite therapeutic approaches by combining modified quinone structures with specific pharmacokinetic properties to achieve both therapeutic efficacy and improved drug delivery characteristics
2Ease of operation
If current therapies are used for mitochondrial dysfunction, then symptom alleviation is achieved, but underlying mitochondrial dysfunction is not addressed
Solution Approach 1:
The patent extracts and addresses the root cause by designing compounds that directly target and restore mitochondrial function (taking out the underlying dysfunction) rather than merely treating symptoms, using quinone derivatives that specifically enhance mitochondrial energy production and protect mitochondrial integrity
3Reliability
If existing treatments are administered, then some therapeutic benefit is obtained, but side effects are increased due to poor bioavailability and high liver metabolism
Solution Approach 1:
The patent changes pharmacokinetic parameters of the therapeutic compounds by modifying chemical structure to reduce hepatic metabolism and improve bioavailability, thereby maintaining therapeutic benefits while reducing liver-related side effects and improving overall safety profile
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds demonstrate improved cytoprotective effects, increased ATP levels, and significant protection against mitochondrial toxicity, offering therapeutic benefits for a range of mitochondrial-related diseases with enhanced bioavailability and reduced side effects compared to existing treatments.
Implementation Method 1
The primary function of the mitochondria is to produce energy in the form of adenosine triphosphate (ATP) via oxidative phosphorylation
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The invention relates to compounds of Formula (I) and methods for their preparation. Also described are pharmaceutical compositions comprising a compound of Formula (I) and their use in the treatment or prevention of conditions associated with mitochondrial dysfunction. Formula (I)